Dose-Limiting Toxicity (DLT)

Dose-Limiting Toxicity (DLT) designates a treatment-related adverse event severe enough to prevent further dose escalation in a clinical trial, establishing boundaries for safe dosing. DLT definitions are protocol-specific and typically focus on clinically significant toxicities occurring within a defined observation window after treatment initiation. Identifying DLTs is central to determining maximum tolerated dose and guiding dose selection for subsequent trial phases.

The biopharmaceutical industry relies on DLT evaluation particularly in oncology trials where balancing efficacy against toxicity is critical. DLT criteria may include severe haematological toxicities, organ dysfunction, or immune-mediated adverse events requiring intervention. Clinical trial teams monitor participants intensively during early dosing periods, with independent safety committees reviewing emerging data to ensure appropriate risk management. DLT outcomes influence escalation decisions, cohort expansion, and recommended dosing regimens. As trial designs become more adaptive and biomarker-driven, DLT frameworks increasingly incorporate mechanistic toxicity understanding and supportive care strategies that enable safer exploration of effective dose ranges.